Boehringer Ingelheim to Pay $95M for Off-Label Promoting
Pharmaceutical giant Boehringer Ingelheim has agreed to pay $95 million to settle claims that the company promoted drugs for off-label uses and at higher doses than those approved by federal health care programs. The settlement was reached with the Justice Department on October 25, 2012.
Drugs Involved in the Settlement Agreement
- Aggrenox (stroke-prevention drug)
- Combivent (chronic obstructive pulmonary disease drug)
- Atrovent (chronic obstructive pulmonary disease drug)
- Micardis (high-blood-pressure drug)
Boehringer Ingelheim Paid Doctors to Promote Drugs
In addition to the off-label scheme, the settlement also settles allegations that the company paid kickbacks to doctors to get them to prescribe the drugs to patients. According to reports, healthcare professionals were compensated by way of payments for participating in advisory boards and in speaker training and consultant programs.
Contact an Experienced Pharmaceutical Industry Attorney
Thomas J. Henry are leaders in the area of drug and product liability litigation. Our Defective Drug and Products Division have extensive knowledge and resources in order to represent our clients efficiently and aggressively. The Defective Drug and Products Division represent a multitude of people who are battling against manufacturers of medical devices and/ or defective pharmaceuticals.
If you or a loved one have been injured by or have developed serious side-effects from the use of a drug or pharmaceutical product, contact Thomas J. Henry immediately. We are available 24/7, nights and weekends.